Purdue Pharma v. Accord Healthcare: Federal Circuit Affirms Oxycodone Patent Portfolio
Purdue Pharma, Purdue Pharmaceuticals LP, and Rhodes Technologies successfully defended seven patents covering tamper-resistant oxycodone dosage forms and low-impurity oxycodone hydrochloride against generic challenger Accord Healthcare. The Federal Circuit issued an unqualified affirmance after 580 days of appellate proceedings, reinforcing the enforceability of Purdue’s formulation IP.
Federal Circuit locks in Purdue’s oxycodone formulation patents against generic entry
Filed on 30 May 2023, Case No. 23-1953 is an ANDA-linked pharmaceutical patent infringement appeal before the Court of Appeals for the Federal Circuit. Purdue Pharma, Purdue Pharmaceuticals LP, and Rhodes Technologies jointly asserted seven patents — including US10407434B2, US9763886B2, US9073933B2, US9763933B2, US9522919B2, and US9775808B2 — covering tamper-resistant oxycodone dosage forms and oxycodone hydrochloride formulations containing fewer than 25 ppm of the impurity 14-hydroxycodeinone. The accused product was Accord Healthcare Ltd.’s proposed generic oxycodone formulation.
The Federal Circuit issued its judgment on 30 December 2024, ordering an unqualified affirmance of the district court’s decision below. The court found no reversible error in the underlying findings, meaning the infringement and/or validity determinations entered against Accord Healthcare remain fully intact. For Purdue and its co-plaintiffs, the affirmance prevents Accord from launching a generic product based on the challenged ANDA entry and preserves the enforceability of all seven asserted patents through their respective terms.
At 580 days, the appeal ran longer than many Federal Circuit ANDA matters, consistent with a multi-patent record requiring substantive claim construction and technical briefing. The basis of termination is listed as ‘Appeal Dismissed’ in the docket, yet the operative order is an affirmance on the merits — a combination that sometimes reflects a procedural consolidation or partial dismissal of specific issues rather than a pure procedural exit. The specific claim-by-claim reasoning and any written opinion remain the definitive record; without a published opinion, the precise doctrinal grounds affirmed cannot be confirmed from the public docket alone.
Filing to Appeal Dismissed in 580 days
580 days — above the median Federal Circuit ANDA appeal duration, suggesting substantive briefing complexity
Federal Circuit affirms: what the ruling means for both parties
Affirmance means the lower decision survives intact
When the Federal Circuit issues an ‘AFFIRMED’ order, it signals that the appellate panel found no reversible error in the district court’s legal conclusions or factual findings. The standard of review applied — de novo for claim construction, clear error for underlying facts — means Accord bore a demanding burden to overturn each holding. An unqualified affirmance leaves every element of the lower ruling undisturbed and forecloses further challenge at this appellate tier.
No reversible error foundAll seven Purdue patents emerge enforceable and intact
For Purdue Pharma, Purdue Pharmaceuticals LP, and Rhodes Technologies, the affirmance is commercially significant: each of the seven asserted patents retains full enforceability against Accord Healthcare’s proposed generic. Accord’s ANDA pathway to market remains blocked under the affirmed infringement or validity findings. The ruling strengthens Purdue’s ability to enforce the same patents against other potential generic challengers who may cite this Federal Circuit outcome as precedent on claim scope or validity.
Patents fully enforceableAccord’s appellate options are exhausted at this level
For Accord Healthcare, the Federal Circuit affirmance closes the primary appellate avenue. The options remaining are narrow: a petition for rehearing en banc (rarely granted), a petition for certiorari to the US Supreme Court (granted in fewer than 1% of patent cases), or commercial negotiation. Accord cannot re-litigate the same patent validity or infringement questions in the district court on the affirmed record. The practical effect is continued exclusion from the oxycodone formulation market covered by Purdue’s patents.
Generic market entry blockedAffirmance raises the bar for opioid formulation generic entry
The Federal Circuit’s endorsement of the district court’s holdings on tamper-resistant oxycodone and low-impurity oxycodone hydrochloride formulations signals judicial confidence in this category of pharmaceutical process and formulation patents. Other ANDA filers targeting Purdue’s oxycodone portfolio face a strengthened prior precedent. Companies developing competing opioid formulations should conduct rigorous FTO analysis against the affirmed patent claims before advancing ANDA or NDA filings — particularly for low-impurity or abuse-deterrent dosage form technologies.
Strengthened formulation IPFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Purdue Pharma | Individual | Pharmaceutical patent holder — developer of tamper-resistant oxycodone and low-impurity opioid formulation IPSearch in Eureka ↗ |
| Co-Plaintiff | Purdue Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Co-Plaintiff | Rhodes Technologies | Company | Search in Eureka ↗ |
| Defendant | Accord Healthcare, Ltd. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for oxycodone hydrochloride productsSearch in Eureka ↗ |
| Plaintiff counsel | Alexander G. Siemers | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Daniel Brown | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | David Kowalski | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Gasper LaRosa | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Gregory A. Castanias | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Gregory G. Garre | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Jennifer L. Swize | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | John Joseph Normile | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Margaret Upshaw | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff counsel | Pablo Daniel Hendler | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff law firm | Jones Day | Law Firm | Representing Purdue PharmaSearch in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins LLP | Law Firm | Representing Purdue PharmaSearch in Eureka ↗ |
| Plaintiff law firm | Potomac Law Group PLLC | Law Firm | Representing Purdue PharmaSearch in Eureka ↗ |
| Defendant counsel | Alejandro Menchaca | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Ben Mahon | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Bradley P. Loren | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant law firm | McAndrews, Held & Malloy Ltd. | Law Firm | Representing Accord Healthcare, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is an unconditional affirmance with no remand, no partial reversal, and no vacatur of any specific holding. At the appellate level, such language confirms the panel applied the applicable standards of review (de novo for legal questions including claim construction; clear error for factual findings) and found the district court’s determinations across all seven patents legally and factually sound. For Accord Healthcare, there is no issue preserved for a further bite at the same facts; for Purdue and its co-plaintiffs, every affirmed holding on infringement and/or validity has the force of Federal Circuit precedent.
US10407434B2 — Tamper-resistant oxycodone and low-impurity opioid formulations
The lead patent, US10407434B2, derives from application US16/262683 and sits within a dense family of continuation and related applications covering oxycodone hydrochloride compositions characterised by low concentrations of the process-related impurity 14-hydroxycodeinone (below 25 ppm), as well as tamper-resistant physical and chemical properties. The family spans applications filed across multiple years — from US13/366755 (US9073933B2) through later continuations — indicating a prosecution strategy designed to maintain forward patent coverage as formulation and manufacturing claims evolved.
Strategically, this portfolio is significant because it protects both the finished dosage form (abuse-deterrent OxyContin-class products) and the underlying API purity requirements — two independent layers of exclusion. Competitors developing oxycodone extended-release generics must navigate not only the tamper-resistance claims but also the impurity specification claims, which may implicate API manufacturing processes upstream. The Federal Circuit’s affirmance reinforces that these claim layers collectively survived invalidity and non-infringement challenges at both the district and appellate levels, materially narrowing the freedom-to-operate space for generic and branded opioid developers alike.
Should you run an FTO against US10407434B2 and Purdue’s oxycodone portfolio?
Any company developing extended-release oxycodone formulations, tamper-resistant opioid dosage forms, or oxycodone hydrochloride API with impurity profiles touching the sub-25 ppm 14-hydroxycodeinone threshold should treat this patent family as a priority FTO target. The Federal Circuit affirmance means the asserted claims have cleared the highest domestic appellate bar available to Accord — elevating their enforceability risk profile. ANDA applicants, NDA 505(b)(2) sponsors, and API manufacturers supplying oxycodone products are all potentially within the claim scope of one or more of the seven affirmed patents.
PatSnap Eureka’s FTO Search Agent can map your oxycodone formulation or API process against the full claim set of each of the seven affirmed patents — including US10407434B2, US9763886B2, US9073933B2, US9763933B2, US9522919B2, and US9775808B2 — and surface design-around opportunities or blocking claim positions. Eureka’s citation network analysis also identifies related applications in the Rhodes Technologies and Purdue family that may extend protection beyond the patents litigated in Case No. 23-1953.
Run a freedom-to-operate analysis on US10407434B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ANDA opioid formulation patent appeals
Federal Circuit appeals involving ANDA challenges to tamper-resistant and low-impurity opioid formulation patents share overlapping claim construction and obviousness frameworks with Case No. 23-1953.
What this case signals for the opioid formulation patent landscape
A seven-patent Federal Circuit affirmance in an ANDA opioid case carries outsized signalling value for generic pharmaceutical IP strategy.
Multi-patent portfolios create compounding generic entry barriers
Purdue’s deployment of seven patents across overlapping oxycodone formulation claims — covering impurity thresholds, tamper resistance, and dosage form design — illustrates a layered exclusion strategy. A generic challenger must successfully invalidate or design around every patent in the portfolio. The Federal Circuit’s affirmance confirms that this layering approach withstood appellate scrutiny, offering a model for pharma IP teams protecting abuse-deterrent or specialty formulations.
ANDA challengers face a heavier burden after a Federal Circuit affirmance
Any subsequent generic filer referencing the same oxycodone technology now confronts adverse Federal Circuit authority on claim scope and validity. Litigation counsel advising ANDA applicants in the tamper-resistant opioid space should assess whether a design-around is commercially viable before filing a Paragraph IV certification that triggers Purdue’s now-strengthened patent portfolio — including the affirmed low-impurity hydrochloride claims.
Pharma v Accord — key questions answered
The Federal Circuit issued an unqualified affirmance of the district court’s decision, finding no reversible error across all seven asserted patents covering tamper-resistant oxycodone and low-impurity oxycodone hydrochloride formulations. The ruling blocks Accord Healthcare’s ANDA-based generic market entry and leaves all affirmed holdings on infringement and validity intact.
Seven patents were asserted: US10407434B2, US9763886B2, US9073933B2, US9763933B2, US9522919B2, US9775808B2, and US763933A. The patents collectively cover oxycodone compositions, oxycodone hydrochloride with fewer than 25 ppm 14-hydroxycodeinone, and tamper-resistant opioid dosage forms.
The affirmance means Accord Healthcare’s ANDA pathway to market for the challenged oxycodone formulations remains legally blocked under the district court’s affirmed findings. Accord’s remaining options are a petition for en banc rehearing, a Supreme Court certiorari petition, or commercial negotiation — all of which are statistically unlikely to succeed. Accord cannot re-litigate the same validity or infringement questions on the affirmed record.
14-hydroxycodeinone is a process-related impurity arising during oxycodone synthesis that carries its own pharmacological activity. Purdue’s patents claim oxycodone hydrochloride compositions containing fewer than 25 ppm of this impurity — a specification that may implicate both product purity and the upstream manufacturing process. Competitors whose API or finished products meet or approach this threshold face potential infringement exposure under the affirmed claims.
Rhodes Technologies, a Purdue affiliate focused on active pharmaceutical ingredient manufacturing, joined Purdue Pharma and Purdue Pharmaceuticals LP as a co-plaintiff. Its inclusion suggests that one or more asserted patents cover API-level processes for producing oxycodone hydrochloride — not solely finished dosage form IP — meaning generic manufacturers and API suppliers may face independent infringement exposure beyond the branded drug product claims.
PatSnap Eureka searches patents and litigation data to answer instantly.